Q: hi folks, thoughts on Q2 results for Docebo...buy/hold/sell...thx jb
5i Research Answer:
EPS of 29c beat estimates of 21c; revenue of $60.7M beat estimates of $58.7M. EBITDA of $9.2M beat estimates by 7%. EPS rose from 26c last year. Sales rose 14%. Growth guidance was increased to 10.75%+ on subscription revenue from 10%+ and total revenue to 10%+ from 9%+. Canaccord raised its target to $46 from $43. The balance sheet is solid with $92M net cash. This was a nice improvement, but the stock is still down 35% this year and still expensive at 34X earnings. HOLD.